On Feb. 21, 2018, Merck & Co. announced that it has acquired Viralytics, an oncology-focused biopharmaceutical company based in Sydney, Austrailia for $394 million.
The transaction has been set for AUD$1.75 cash (US$1.37) per Viralytics share. Merck reports that the proposed acquisitioOriginal Article
